Panayotova et al. published a multicenter, randomized, noninferiority trial which sought to compare liver preservation using the LifePort Liver Transporter to the standard of care, static cold storage. The study included 142 liver transplant procedures from 9 US centers, and compared outcomes such as early allograft dysfunction, L-GrAFT7 score, primary nonfunction, biliary strictures, and non-anastomotic biliary strictures.
They found that:
- Lower incidence of EAD in HMP-O2
- Risk of graft failure as predicted by L-GrAFT7 was lower in HMP-O2
- Lower incidence of PNF in HMP-O2
- Lower incidence of biliary strictures in HMP-O2
- Severe non-infectious adverse events were almost 3x more common in SCS
They concluded that HMP-O2 with LifePort Liver Transporter is safe and efficacious for liver graft preservation compared to SCS.
Read the full article here: https://journals.lww.com/hep/abstract/9900/portable_hypothermic_oxygenated_machine_perfusion.678.aspx
The Latest
